Elanco Animal Health, Inc. Stock News

Conditional Approval Marks Elanco's Third New World Screwworm Treatment Option for Companion Animals, Providing Multiple Treatment Solutions Prior to Fly Being Detected in the U.S. FDA's Conditional Approval of Credelio Quattro-CA1 (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) is the first for companion animals against New World screwworm Action follows previous Emergency...

Elanco Animal Health Incorporated (ELAN) Analyst/Investor Day Transcript

Elanco Animal Health CEO Jeff Simmons says the company is in the best position it's been in years. Elanco stock has surged in 2025.

Details three-year outlook with annual mid-single digit top-line organic constant currency growth driven by a consistent flow of high-impact innovation, high-single digit adjusted EBITDA growth and low double-digit adjusted EPS growth, all starting in 2026. Expects further net leverage ratio improvement to

Elanco Animal Health Incorporated (ELAN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Elanco Animal Health Incorporated (ELAN) Presents at Evercore 8th Annual Healthcare Conference Transcript

MELBOURNE, Australia , Nov. 26, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Deve...

The U.S. Food and Drug Administration on Friday authorized emergency use of Elanco Animal Health's chewable tablet to treat the infestation of a parasite in cats known as New World screwworm.